B
edaquiline is a diarylquinoline and was approved by the United States Food and Drug Administration (FDA) in 2012 under the accelerated-approval program. This drug is indicated for treatment of multidrug-resistant pulmonary tuberculosis (MDR-TB) in combination with other active anti-TB drugs in adults without other treatment options (1) . This new anti-TB drug, formally known as TMC207, showed exposure-dependent killing of Mycobacterium tuberculosis (2, 3) . The drug is metabolized by cytochrome P 450 enzyme 3A4 (CYP3A4) to its 5-foldless-active metabolite N-monodesmethyl bedaquiline (M2) (4) .
Bedaquiline therapy is started in a loading dose of 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks. This dosing regimen was chosen because pharmacokinetics (PK) modeling predicted gradual accumulation in plasma and tissues (4) .
At this time, little data on PK in patients with advanced MDR-TB or suffering from comorbidities are available apart from the data that were collected in the clinical studies (4) . However, variability in the PK of antituberculosis drugs is considerable and altered drug exposure may translate to variations in clinical outcomes (5, 6) . Clearly, there is a need for more-descriptive (population) PK studies on bedaquiline to determine predictors of exposure, drug-drug interaction (7) , and PK-pharmacodynamics (PD) relationships. The World Health Organization has released a guide for the use of bedaquiline and encourages additional evaluation of this new drug (8) .
As bedaquiline serum concentrations may be altered in MDR-TB patients with comorbidities, a suitable method of analysis is needed. Only advanced analytical methods using high-performance liquid chromatography (HPLC) inductively coupled plasma (ICP) mass spectrometry (MS) have been presented previously (9, 10). These methods were used for metabolite profiling of bedaquiline in feces. Due to their advanced setup requirements, these analytical procedures are generally not available in clinical laboratories that perform routine monitoring of serum concentrations of anti-TB drugs. In addition, despite their advanced setup, the results determined with the combination of HPLC and ICP are not as specific as those determined with tandem mass spectrometry (MS/MS), as it measures only the bromine. Simpler analytical methods using liquid chromatography coupled to tandem mass spectrometry are described in reports of the clinical studies, but the data lack the detail necessary to be useful for clinical laboratories as guidance to develop their own analytical methods (11) . Therefore, the purpose of this study was to develop a simple and robust LC-MS/MS method without extensive sample processing, using deuterated bedaquiline as the internal standard, to quantify bedaquiline and M2 serum concentrations in MDR-TB patients.
MATERIALS AND METHODS
Analysis. Bedaquiline, M2, and D6-bedaquiline (internal standard) ( Fig.  1) were obtained from Janssen Pharmaceuticals (Beerse, Belgium). Water, acetonitrile, ammonium acetate, and acetic acid were all of suitable analytical grade. Pooled human serum samples were made available according to the guidelines of the University Medical Center Groningen.
Bedaquiline stock solutions of 500 mg/liter of dimethyl sulfoxide (DMSO)-methanol (50:50) were prepared separately and used for the preparation of calibration standards and quality control (QC) samples using blank human serum. The amounts of stock solution added to the serum did not exceed 5% of the total volume. Calibration standards and QC samples were freshly prepared on the first validation day and stored at Ϫ20°C for use on the other validation days. Concentrations of the standards and QC samples are listed in Table 1 . The internal standard solution was prepared by diluting a 500 mg/liter bedaquiline-D6 stock solution to 0.1 mg/liter with methanol-acetonitrile (precipitation reagent) (160:840).
Samples were prepared by adding 750 l precipitation reagent to 10 l serum and subsequent vortex mixing for 1 min. The vials were centrifuged for 5 min at 11,000 rpm, and 5 l of the upper layer was injected into the LC-MS/MS system.
The analysis was performed on a triple-quadrupole LC-MS/MS system (Thermo Scientific, San Jose, CA, USA) with a MS Pump Plus and Surveyor autosampler (Finnigan). The mass spectrometer was a TSQ Quantum Access Max mass spectrometer. The temperature of the autosampler was set at 10°C. A HyPURITY C 18 analytical column (Thermo Scientific, Interscience, Breda, The Netherlands) (50 by 2.1 mm; pore size, 3 m) was used for chromatographic separation, and the temperature was set at 20°C. The mobile phase had a flow rate of 500 l/min and consisted of purified water, acetonitrile, and an aqueous buffer (containing ammonium acetate [10 g/liter], acetic acid [35 mg/liter], and trifluoroacetic anhydride [2 ml/liter] in water). The elution gradient is shown in Table 2 . The method had a run time of 2.6 min.
The MS system was configured using the positive electrospray ionization mode and selected reaction monitoring (SRM) with a spray voltage of 3,500 V, a capillary temperature of 350°C, and sheath gas and auxiliary pressures of 35 and 10 arbitrary units, respectively. Mass transitions for bedaquiline were 555.1 m/z to 58.4 m/z, for D6-bedaquiline were 561.2 m/z to 64.4 m/z, and for M2 were 541.1 m/z to 480.1, using a scan width of 0.5 m/z. Collision energy was determined at 34 electron volts (eV) for both transitions. Xcalibur software version 2.0.7 (Thermo Fisher, San Jose, CA, USA) was applied for peak height and peak area integration for all components.
Analytical method validation. The criteria for validation of the method included selectivity and sensitivity (i.e., determination of the lower limit of quantitation [LLOQ]), linearity, accuracy and precision, recovery, matrix effect, process efficiency, and dilution integrity. The calibration curve for bedaquiline consisted of 8 samples with concentrations of 0.05, 0.25, 0.50, 1.00, 2.00, 4.00, 5.00, and 6.00 mg/liter. Quality control (QC) samples with 4 different concentrations of bedaquiline were used, where the LLOQ was 0.05 mg/liter, the low concentration was 0.25 mg/ liter, the medium concentration was 2.50 mg/liter, and the high concentration was 5.00 mg/liter. The effect of endogenous substances was examined by an infusion ion suppression test using 6 lots of different blank serums, and the results were compared to the response seen at the LLOQ. During 3 days, a single calibration curve was analyzed each day and accuracy was measured by evaluation of five determinations per QC sample on three consecutive days. Precision was divided into within-run and between-run data using the same method as described above for the accu- Procedures to evaluate recovery, matrix effect, and process efficiency were derived from the work of Matuszewski and coworkers (12) . The recovery was calculated by dividing the peak area value of the extract of the spiked matrix by the peak area value of the spiked extract of a blank matrix. The matrix effect was tested by dividing the peak area value of the spiked extract of the blank matrix by the peak area value of the spiked extraction solution. The process efficiency was determined by dividing the peak area value of the extract of the spiked matrix by the peak area value of spiked extraction solution. Recovery, matrix effect, and process efficiency were all determined at three concentrations (low, medium, and high) in quintuplicate in a single run. To determine the dilution integrity, on three consecutive days, a QC sample with bedaquiline at a concentration of 12 mg/liter plasma was diluted 10 times and then analyzed in quintuplicate.
The stability of bedaquiline and M2 was tested under different test conditions, including storage stability and freeze-thaw stability at lowand high-level QC. The storage stability of bedaquiline and M2 was examined by storing QC samples at room temperature (20°C Ϫ25°C), in a refrigerator at 4°C, and after sample preparation in the autosampler at 10°C. Stability was also tested using five freeze-thaw cycles at Ϫ20°C. All stability tests were done using two different QC levels (low and high) in five determinations per concentration. Stability values were defined in terms of changes in concentration and should be Յ15%. Long-term sample stability was not tested, as data were provided by Janssen Pharmaceuticals.
Clinical application and compassionate-use program. Bedaquiline was made available in a compassionate-use program in The Netherlands before it became commercially available. Data were collected through review of the medical records of the patients who received bedaquiline within the compassionate-use program. Informed consent was obtained from the participants. The study was evaluated by the local ethics committee and was found to be in accordance with Dutch legislation due to its retrospective nature (METc 2013-491).
RESULTS
The mean retention time of bedaquiline was 1.9 min, the mean retention time of bedaquiline-D6 was also 1.9 min, and the mean retention time of M2 was 1.8 min (Fig. 2) . Examining the selectivity of this analytical method, no interfering peaks from endogenous substances were observed at the retention time of bedaquiline or M2 in any of the six different lots of human serum (Fig. 2) .
The calibration curves were linear over a range of 0.05 (LLOQ) to 6.00 mg/liter, and the correlation coefficient (R 2 ) values were 0.997 for bedaquiline and 0.999 for M2. The calibration curve parameters are presented in Table 3 . The calculated accuracy ranged from 1.9% to 13.6% for bedaquiline and 2.9% to 8.5% for M2. Within-run precision ranged from 3.0% to 7.2% for bedaquiline and 3.1% to 5.2% for M2, and between-run precision ranged from 0.0% to 4.3% for bedaquiline and 0.0% to 4.6% for M2. The results of the accuracy and precision determinations for all QC levels for bedaquiline and M2 are shown in Table 3 .
Recovery, matrix effect, and process efficiency data for bedaquiline and M2 are displayed in Table 1 .
Results of determinations of the stability of bedaquiline and M2 under different test conditions are shown in Table 4 . Measured (low and high) concentrations of QC samples for the freezethaw stability biased between 7.2% and 9.0% for bedaquiline and between 7.7% and 8.0% for M2, compared to the initial concentrations. Stability was determined by measuring QC samples stored at 4°C, and data differed by 1.1% to 4.4% from the nominal concentrations. After storage at room temperature for 72 h, the concentrations biased from Ϫ11.6% to Ϫ6.6% for bedaquiline and Ϫ7.8% to 0.5% for M2, compared to the initial concentrations. After sample preparation, the concentrations stored in the autosampler for 240 h biased between 3.5% and 6.7% for bedaquiline and between 2.0 and 2.6% for M2 from the nominal concentrations. Samples were stable for Ͼ1 year at Ϫ20°C for bedaquiline and M2 (data on file).
Clinical application; compassionate-use program. A 31-year-old female who resided in a highly TB-burdened country presented with fever despite having received two short courses of antimicrobial drugs. Her chest X-ray revealed characteristic signs of TB. M. tuberculosis was isolated from the sputum, revealing resistance to isoniazide, rifampin, ethambutol, and moxifloxacin.
She was started on a regimen containing pyrazinamide, kanamycin, linezolid, and prothionamide. Nausea and vomiting necessitated replacement of prothionamide by cycloserine. After 4 months of treatment, bedaquiline, provided in a compassionateuse program, was added to optimize the treatment regimen. As part of routine supportive care, the MDR-TB treatment regimen was further optimized based on MIC testing and measurements of drug serum concentrations. The concentration-time profiles of bedaquiline and M2 can be observed in Fig. 3 . Bedaquiline drug concentrations at the end of treatment were higher than the values previously reported at week 8 (13) . M2 values were low, as expected (3) . No drug-drug interactions were expected as no CYP3A4 inhibitors were coadministered. As the treatment was nearly completed and, more importantly, the patient tolerated the drug very well, no dose adjustments were made.
DISCUSSION
This report describes the design and validation of a simple and rapid analysis method using a triple-quadrupole LC-MS/MS system for the quantification of bedaquiline and its metabolite M2 in human plasma and deuterated bedaquiline as the internal standard. This LC-MS/MS method showed good accuracy and precision. The calibration curve was linear within a range of 0.050 (LLOQ) to 6.00 mg/liter and was found to be in accordance with the expected bedaquiline and M2 concentrations in serum (11, 13) .
Compared to the analytical range of the procedure described by Rustomjee and coworkers (11) , the analytical range of our procedure had an elevated higher limit of quantitation (HLQ) (2.0 versus 6.0 mg/liter). This may be advantageous, as dilution of the sample and subsequent rerun of a diluted sample become superfluous. However, our LLOQ was a little higher. This was of no clinical relevance, as the LLOQ of our procedure was designed for patients on bedaquiline treatment.
As already mentioned, a major advantage of this LC-MS/MS method is that it uses a simple protein precipitation which makes it suitable for PK monitoring. The two ICP-MS methods described earlier used liquid-liquid extraction and solid-phase extraction and were specifically designed for metabolite profiling and not for PK monitoring (9, 10) . The run time is very short since the retention time of bedaquiline is 1.9 min. This facilitates high sample throughput. This is in line with the strategy of the World Health Organization designed to increase the capacity of highquality laboratory systems using modern diagnostics for early, rapid, and accurate detection of TB, as it demands only one LC-MS/MS system to support a clinical therapeutic drug monitoring (TDM) service (14) . In addition, bedaquiline sample stability is sufficient to enable transportation to a centralized laboratory. Recently, the first results of an international proficiency testing program for measurement of tuberculosis drugs were presented (15) . Programs for drug susceptibility testing have been around for many years (16) , but programs for measuring tuberculosis drug plasma concentrations have not. Participation in such an interlaboratory program provides additional quality assurance on top of intralaboratory QC monitoring, ensuring that plasma drug concentrations are measured accurately. In our opinion, bedaquiline should be used in such a program when plasma levels are measured frequently.
Since the antimicrobial action of bedaquiline is exposure dependent (2, 3) , it is necessary, as with any drug with exposuredependent killing characteristics, that target exposures are reached. Current data from animal studies on optimal drug exposure have not yet been translated to and validated in human studies. Due to the lack of clinical phase III data, including intensive PK sampling, MIC evaluation, and clinical outcome data, no clear target can be given. Hopefully, the data from the STREAM trial (NCT02409290) will provide relevant data. An average steadystate plasma concentration of 0.6 mg/liter was observed in patients who received bedaquiline in addition to a background regimen, showing a culture conversion rate higher than that seen with patients who received a placebo (13) . To attain this target in patients suspected to have altered pharmacokinetics due to reduced food intake, drug-drug interactions, or altered disease state, bedaquiline serum concentration measuring may be helpful. We should try to optimize treatment in order to prevent treatment failure, especially in patients infected with extensively resistant M. tuberculosis strains with few treatment options left (17) . For first-line treatment, it has already been shown that drug exposure predicts outcomes (6) . In cases of treatment of MDR-TB, that conclusion is less clear, predominantly due to a lack of data. A recent study showed that fluoroquinolone resistance developed in over 10% of the patients studied (18) , likely because the pharmacokinetic-pharmacodynamic targets were not reached in a substantial proportion of the patients (19) . Recent phase III studies evaluating new strategies for treatment of TB did not include measurements of drug concentrations as a covariate in the analysis of the primary outcome of the study (20) (21) (22) . As evaluation of drug concentrations in relation to the susceptibility of the pathogen may help to explain differences in treatment responses, it is highly desirable that pharmacokinetics should become part of future phase III studies (23) . Therefore, plasma drug concentrations of new drugs such as bedaquiline and delamanid will receive more attention in future studies as well as in daily practice. Also, in cases of off-label use or in studies evaluating the bactericidal activity of drug combinations, information on drug exposure is helpful to explain treatment outcome (24) (25) (26) .
The described method was developed for monitoring bedaquiline serum concentrations in daily practice because it meets the criteria for TDM but is also suitable for clinical pharmacokinetic studies or clinical trials to further investigate the use of bedaquiline in specific TB patient groups suffering from comorbidities or drug-drug interactions.
Conclusion. A simple LC-MS/MS method to quantify bedaquiline and M2 in human serum using deuterated bedaquiline as the internal standard has been developed and validated. This method can be used in daily practice and in clinical studies evaluating drug exposure in relation to clinical outcome.
